Researchers have demonstrated unprecedented capabilities of artificial intelligence in protein and genome editing design, surpassing natural biological processes. Collaborations between Integra Therapeutics, Pompeu Fabra University, and others have produced synthetic proteins enhancing genome editing efficiency. Concurrently, Microsoft researchers revealed that generative AI can redesign toxic proteins to bypass biosecurity screening, highlighting emerging dual-use biosecurity challenges. These developments underscore both the extraordinary potential and risks of AI-driven biotechnology, emphasizing the need for vigilant oversight alongside innovation.